FAScinate Therapeutics Completes Part 1a of Phase 2 Study of Company's Parkinson’s Disease Drug Candidate "KM-819"Read Now >
Thursday, January 12, 2023 / PRWeb
The latest updates on drug candidate KM-819.
FAScinate Therapeutics, Inc. Cleared for Phase 2 Clinical Trials of Company’s Parkinson’s Disease Treatment with Approval from U.S. Food and Drug AdministrationRead Now >
Tuesday, November 23, 2021 / BioSpace